Match Document Document Title
US20070178091 Combination Therapy  
The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various...
US20070154477 Humanized anti-CD3 specific antibodies  
Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.
US20070134241 Humanized anti-CD3 specific antibodies  
Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.
US20070086979 Methods and compositions for use in treatment of patients with autoantibody positive disease  
The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method...
US20070077247 Receptor on the surface of activated T-cells: ACT-4  
The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis...
US20070065437 Anti-CD3 antibody formulations  
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages.
US20070025987 Method for Treating Vasculitis  
A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist...
US20070020265 IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS  
Antibodies that bind with a B-cell antigen provide an effective means to treat autoinmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
US20070014797 Method for treating Sjogren's syndrome  
A method of treating Sjögren's syndrome in a patient eligible for treatment is provided involving administering an effective amount of an antagonist that binds to a B-cell surface marker to the...
US20070014720 Antibodies directed to CD20 and uses thereof  
Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences...
US20060246004 Antibody variants and uses thereof  
The invention provides improved humanized CD20 binding antibodies for treatment of B cell malignancies and autoimmune diseases.
US20060240009 Liposome composition for improved intracellular delivery of a therapeutic agent  
A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and...
US20060240007 Method for treating dementia or Alzheimer's disease  
Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described.
US20060239910 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells  
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate...
US20060233791 Anti-CD19 antibodies and uses in oncology  
The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using...
US20060193887 Medical devices having nanoporous bonding layers  
The present invention relates generally to medical devices with therapy eluting components and methods for making same. More specifically, the invention relates to implantable medical devices...
US20060193856 Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof  
The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said...
US20060177443 Integrin antagonists  
The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration, and for inhibiting angiogenesis. In...
US20060110387 Method for treating vasculitis  
A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist...
US20060088526 Humanized anti-CD3 specific antibodies  
Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.
US20060062787 Method for treating Sjogren's syndrome  
A method of treating Sjögren's syndrome in a patient eligible for treatment is provided involving administering an effective amount of an antagonist that binds to a B-cell surface marker to the...
US20060008532 Complexes of protein crystals and ionic polymers  
The present invention relates to complexes of protein crystals and ionic polymers and compositions comprising such complexes. The invention further provides methods for producing these complexes...
US20050287141 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease  
An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC)...
US20050276803 Method for augmenting B cell depletion  
The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing...
US20050271660 Nebulization of monoclonal antibodies for treating pulmonary diseases  
The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or...
US20050271658 Preventing autoimmune disease  
The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by...
US20050201994 Human CTLA-4 antibodies and their uses  
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells  
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
US20050095243 Combination therapy for B cell disorders  
The invention provides methods of treating B cell based malignancies and B-cell regulated autoimmune disorders using a combination therapy of anti-CD20 antibody with a BLyS antagonist.
US20050037005 5c8 Antigen  
This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of...
US20050025764 CD20 binding molecules  
The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a...
US20050002916 Cytokine-expressing cellular vaccine combinations  
The present invention in all of its associated aspects provides improved methods and compositions for treating cancer in a mammal based on the administration of the combination of a...
US20160185870 COMBINING CD27 AGONISTS AND IMMUNE CHECKPOINT INHIBITION FOR IMMUNE STIMULATION  
The present invention relates to treatments of conditions ameliorated by stimulation of an immune response, in particular by the stimulation of antigen-specific T-lymphocytes. Treatment of such...
US20160015805 DRUG COMBINATIONS  
The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit...
US20150273033 COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER  
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a...
US20150239972 METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS  
PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced...
US20150190506 COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS  
The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
US20140234331 HUMAN CTLA-4 ANTIBODIES AND THEIR USES  
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
US20130309226 HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS  
The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a...
US20110280869 METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS  
The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In...
US20110129412 Antibodies Directed to CD20 and Uses Thereof  
Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences...
US20110123531 COMBINATION THERAPY  
The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various...
US20100183612 METHODS OF TREATMENT USING CTLA4 MUTANT MOLECULES  
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4...
US20100080809 GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF  
The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides...
US20090186037 METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH  
The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on...
US20080187540 Antibodies to OCIF-binding molecules  
A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid...
US20070148170 Fc Variants With Optimized Fc Receptor Binding Properties  
The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding...
US20070122407 ISOLATED NUCLEIC ACIDS, VECTORS AND HOST CELLS ENCODING ErbB3 ANTIBODIES  
Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein...
US20070031331 Treatment of Disorders  
The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that...
US20070025990 Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders  
The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In...